Skip to contentE
Emergent BioSolutions Inc.
E
EBSEmergent BioSolutions Inc. Q1 2022 · 10-Q
Revenue$304.80M$304.80M−11.1% vs Q1 2021 Net Income-$4.60M-$4.60MN/M vs Q1 2021 EPS Diluted-$0.09-$0.09N/M vs Q1 2021 Gross Profit$142,000,000−36.2% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Emergent BioSolutions Inc. · CIK 1367644 · Engraved from SEC EDGAR
Operating Cash Flow-$37,300,000N/M Free Cash Flowderived-$69,500,000N/M Margins · derivedGross margin46.6%−18.3 pt vs Q1 2021
Operating margin2.3%−24.6 pt vs Q1 2021
Net margin-1.5%−21.1 pt vs Q1 2021
ended Mar 31, 2022 · filed Apr 29, 2022 · 29 d after period end